Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cardiac Autonomic Neuromodulation in Myocardial Revascularization (CALM): A Multicenter Randomized Controlled Trial of Partial Cardiac Denervation for the Prevention of Postoperative Atrial Fibrillation After Coronary Artery Bypass Grafting

NCT07918781 is registered in ClinicalTrials.gov with China National Center for Cardiovascular Diseases as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07918781 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Cardiac Autonomic Neuromodulation in Myocardial Revascularization (CALM): A Multicenter Randomized Controlled Trial of Partial Cardiac Denervation for the Prevention of Postoperative Atrial Fibrillation After Coronary Artery Bypass Grafting
Lead sponsor
China National Center for Cardiovascular Diseases
Phase
Not applicable
Overall status
Not yet recruiting
Start date
December 1, 2026
Completion date
December 31, 2030
Enrollment
1,470 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

coronary artery disease, postoperative atrial fibrillation

Arms

As registered; 2 arms.

  • Control group No intervention

    CABG alone

  • Intervention group ExperimentalPartial Cardiac Denervation

    Partial cardiac denervation + CABG. Partial cardiac denervation consists of transection of the ligament of Marshall and resection of the Waterston fat pad.

Primary endpoints

Registered primary outcome measures; 2 primary.

  • Incidence of Postoperative Atrial Fibrillation Within 6 Postoperative Days From admission to the intensive care unit after surgery until postoperative day 6.

    The proportion of participants with documented new-onset postoperative atrial fibrillation (POAF). POAF is defined as an episode of atrial fibrillation characterized by irregularly irregular RR intervals and the absence of discernible P waves, lasting more than 30 seconds. Continuous electrocardiographic recordings will be centrally reviewed by the blinded ECG Core Laboratory.

  • Time to First Occurrence of the Composite Clinical Outcome From surgery until 3 years after enrollment of the last participant, with a minimum follow-up of 3 years for each participant.

    Time from surgery to the first occurrence of any component of the composite outcome, including all-cause death, stroke, systemic embolism, myocardial infarction, readmission for cardiac reasons, or post-discharge atrial fibrillation. Suspected clinical events will be adjudicated by an independent Clinical Event Adjudication Committee blinded to treatment allocation. Post-discharge atrial fibrillation events will be reviewed by the blinded ECG Core Laboratory.

Lead sponsor's other trials

China National Center for Cardiovascular Diseases, most recent start first.

Similar trials

Same condition (Coronary Artery Disease) and phase, most recent start first.